PFE - Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
- Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen’s Bavarian Nordic in a $225 million deal.
- Beijing YishengBio completed a $40 million Series C round in a royalty-based transaction with R-Bridge, a division of CBC Group focused on royalty transactions.
- Jiangsu Atom Bioscience said its treatment for gout met its primary efficacy endpoint in a double-blind placebo-controlled Phase IIa trial.
For further details see:
Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal